Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"dNDAs"

This article was originally published in The Tan Sheet

Executive Summary

Approved Rid Mousse "NDA Deviation" may open the door to other such applications being filed with the agency, FDA indicates (1"The Tan Sheet" March 13, p. 4). "dNDAs" allow an applicant to file only that data supporting the proposed change to a monograph drug, such as a new formulation, rather than all of the data required under an NDA. According to FDA regulations, "A new drug application requesting approval of an OTC drug deviating in any respect from a monograph that has become final shall be in the form required by Sec. 314.50 of this chapter, but shall include a statement that the product meets all the conditions of the applicable monograph except for the deviation for which approval is requested and may omit all information except that pertinent to the deviation"
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel